These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2511758)

  • 1. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
    Neu HC; Davidson S; Briones F
    Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of serious infections with intravenous ciprofloxacin.
    Scully BE; Neu HC
    Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Fass RJ; Plouffe JF; Russell JA
    Am J Med; 1989 Nov; 87(5A):164S-168S. PubMed ID: 2589361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of intravenous ciprofloxacin in difficult-to-treat infections.
    Giamarellou H; Galanakis N
    Am J Med; 1987 Apr; 82(4A):346-51. PubMed ID: 3555059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group.
    Modai J
    Am J Med; 1989 Nov; 87(5A):243S-247S. PubMed ID: 2686426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections.
    Peacock JE; Pegram PS; Weber SF; Leone PA
    Am J Med; 1989 Nov; 87(5A):185S-190S. PubMed ID: 2686421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections.
    Gaut PL; Carron WC; Ching WT; Meyer RD
    Am J Med; 1989 Nov; 87(5A):169S-175S. PubMed ID: 2686417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous ciprofloxacin therapy in severe infections.
    Gudiol F; Cabellos C; Pallares R; Linares J; Ariza J
    Am J Med; 1989 Nov; 87(5A):221S-224S. PubMed ID: 2589364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.
    Scully BE; Neu HC
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():179-85. PubMed ID: 3804906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study.
    Villavicencio J; Asensio de Fernandez ME; Ramirez CA
    Am J Med; 1989 Nov; 87(5A):191S-194S. PubMed ID: 2686422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential intravenous/oral ciprofloxacin in the treatment of severe multiresistant gram-negative infections.
    Chayakul P; Krisanapan S; Kalnauwakul S
    J Med Assoc Thai; 1993 Jan; 76(1):35-40. PubMed ID: 8228692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
    Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH
    Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections.
    Levine DP; McNeil P; Lerner SA
    Am J Med; 1989 Nov; 87(5A):160S-163S. PubMed ID: 2686416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections.
    Ramirez-Ronda CH; Saavedra S; Rivera-Vázquez CR
    Am J Med; 1987 Apr; 82(4A):220-3. PubMed ID: 3555040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous ciprofloxacin for infections in cancer patients.
    Rolston KV; Haron E; Cunningham C; Bodey GP
    Am J Med; 1989 Nov; 87(5A):261S-265S. PubMed ID: 2589375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
    Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
    Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of intravenous ciprofloxacin in the treatment of selected infections.
    Abadie-Kemmerly S; Pankey GA
    Am J Med; 1989 Nov; 87(5A):213S-220S. PubMed ID: 2589363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
    Bouza E; Díaz-López MD; Bernaldo de Quirós JC; Rodríguez-Créixems M
    Am J Med; 1989 Nov; 87(5A):228S-231S. PubMed ID: 2589366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections.
    Haddow A; Greene S; Heinz G; Wantuck D
    Am J Med; 1989 Nov; 87(5A):113S-115S. PubMed ID: 2686410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.